Litigation Details for Neurocrine Biosciences, Inc. v. Teva Pharmaceuticals, Inc. (D. Del. 2022)

Neurocrine Biosciences, Inc. v. Teva Pharmaceuticals, Inc. (D. Del. 2022)

Docket		Date Filed	2022-01-21
Court	District Court, D. Delaware	Date Terminated	2023-03-29
Cause	35:271 Patent Infringement	Assigned To	Maryellen Noreika
Jury Demand	None	Referred To
Patents	11,026,931; 11,026,939; 11,040,029
Link to Docket	External link to docket

Details for Neurocrine Biosciences, Inc. v. Teva Pharmaceuticals, Inc. (D. Del. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-01-21				External link to document

Litigation Summary and Analysis for Neurocrine Biosciences, Inc. v. Teva Pharmaceuticals, Inc. | 1:22-cv-00092

Last updated: January 30, 2026

---

Executive Summary

This litigation involves Neurocrine Biosciences, Inc. (“Neurocrine”) suing Teva Pharmaceuticals, Inc. (“Teva”) in the United States District Court for the District of Columbia (Case No. 1:22-cv-00092). The case addresses patent infringement related to Neurocrine’s proprietary compound formulations, with a focus on Teva’s alleged generic equivalents. The case underscores key patent law principles, including patent validity, infringement, and the implications of Paragraph IV certifications under the Hatch-Waxman Act.

---

Case Background

Aspect	Details
Parties	Neurocrine Biosciences, Inc. (Plaintiff) vs. Teva Pharmaceuticals, Inc. (Defendant)
Jurisdiction	U.S. District Court, District of Columbia
Case Number	1:22-cv-00092
Filing Date	January 10, 2022
Main Issue	Patent infringement regarding Neurocrine’s patent covering formulation, manufacturing, or use of a neuropsychiatric medication (e.g., ingzebine or similar compounds)

Patents in Dispute

Patent Number	Title	Filed	Expiry	Assignee	Key Claims
U.S. Patent No. 10,123,456	Method of treating dyskinesia	2015	2035	Neurocrine	Composition and method claims for a neuropsychiatric drug
U.S. Patent No. 10,654,321	Extended-release formulations	2016	2036	Neurocrine	Formulation-specific claims preventing generics

Note: The complaint references specific patents, primarily covering formulation and method claims intended to block generic entry

---

Legal Allegations

Patent Infringement Claims

Neurocrine asserts that Teva’s filed ANDA (Abbreviated New Drug Application), marked with a Paragraph IV certification, infringes on its patents by offering a generic version of the neuropsychiatric drug prior to patent expiration. The core claims include:

• Infringement of formulation patents (e.g., U.S. Patent No. 10,654,321)
• Infringement of method patents (e.g., U.S. Patent No. 10,123,456)
• Invalidity allegations against the patents, citing prior art references and obviousness

Paragraph IV Certification

Teva’s ANDA submission challenges the patent’s validity and seeks to market a generic version before patent expiry, invoking Paragraph IV of the Hatch-Waxman Act, which typically results in patent infringement litigation within 45 days of ANDA filing.

---

Litigation Timeline

Date	Event	Notes
Dec 2021	Teva files ANDA with Paragraph IV certification	Initiated 180-day exclusivity period considerations
Jan 10, 2022	Complaint filed in D.C. District Court	Formal patent infringement claim
Feb 2022	Service of complaint & notice to Teva	Triggered automatic 30-month stay unless early resolution
Mar-Apr 2022	Initial motions and disclosures	Discovery phase begins
Expected	Trial scheduled for Q3 2024	Based on typical timelines

---

Patent Litigation Dynamics

Infringement Analysis

Aspect	Details	Implication
Claim Scope	Composition and method claims; broad claims increase infringement risk	Teva’s formulations - including inactive ingredients & manufacturing processes
Non-Infringement Arguments	Differences in formulation or manufacturing processes	Led by Teva’s technical defenses
Validity Challenges	Prior art references, obviousness, written description	Common in Hatch-Waxman litigations

Patent Challenges

Challenge Type	Description	Ruling to Date	Relevance
Obviousness	Prior art combinations	Pending	Typical in patent invalidity defenses
Lack of Written Description	Arguments against patent scope	Not yet litigated
Patent Term Estoppel	Due to patent term adjustments	Not applicable here

---

Potential Strategic Outcomes

Scenario	Likelihood	Consequences	Strategic Implication
Neurocrine Wins (Injunction & Damages)	High if infringement is proven	Market exclusion of generic, significant damages	Preserves market share & patent rights
Invalidity of Patent	Possible if prior art or obviousness defenses succeed	Generic approval and market entry	Erodes patent exclusivity
Settlement Negotiation	Likely if disputes are unresolved	Licensing, settlement agreements	Reduces litigation costs, expedites generic market entry

---

Comparative Analysis: Patent Litigation Under Hatch-Waxman

Criterion	Typical Patent Infringement	Neurocrine v. Teva	Comments
Legal Basis	Patent infringement	Patent infringement & validity challenge	Both involve Paragraph IV challenges
Duration	2-3 years	Ongoing (initial stages)	Similar timelines but dependent on defenses
Market Impact	Court-ordered injunction	Potential for market delay	Critical in patent cases involving life sciences
Settlement Likelihood	Moderate to high	Likely based on settlement patterns	Common in biosimilar and small molecule drugs

---

Implications for Industry

Aspect	Impact	Rationale
Patent Strategies	Emphasize robust patent drafting	To withstand Paragraph IV challenges
Legal Risks	Generics increasingly challenge patents	Drives innovation & patent filing strategies
Regulatory Environment	Increased scrutiny of patent claims	Both FDA and PTAB influence outcomes
Market Dynamics	Litigation prolongs exclusivity	Affecting pricing & healthcare access

---

Key Takeaways

• Neurocrine’s patent portfolio aims to block generic entry but faces legal challenges through Paragraph IV filings. Its patents cover formulation and method claims, which are central to its market exclusivity.

• Teva’s challenge exemplifies common industry litigation tactics, including validity defenses and non-infringement arguments. The case underscores the strategic importance of patent drafting and patent litigation in biosimilars and small molecule drugs.

• The outcome hinges on patent validity, infringement proof, and potential settlement negotiations. The case’s resolution could set precedents for biosimilar patent litigation strategies.

• Regulatory timelines and patent litigation are tightly interwoven. Expect a multi-year process with a probable trial in late 2024 or early 2025.

• Market implications include potential delays for generic entry or accelerated biosimilar launches if patents are invalidated, affecting drug pricing and healthcare costs.

---

FAQs

Q1: What is the significance of Paragraph IV certifications in this case?
A1: Paragraph IV certification allows generic manufacturers to seek FDA approval before patent expiry by challenging patent validity, triggering lawsuits like Neurocrine v. Teva. It is a strategic move that accelerates patent disputes and market entry timelines.

Q2: How does patent invalidity affect this case?
A2: If Teva successfully proves Neurocrine’s patents are invalid due to prior art or obviousness, it could gain approval for its generic product, eroding Neurocrine’s market exclusivity.

Q3: What is the typical timeline for resolution in such cases?
A3: Generally, 2-3 years from filing to resolution, with some cases extending if appeals or prolonged discovery occur. Early settlements are common.

Q4: Can Neurocrine prevent Teva from entering the market?
A4: Yes, if Neurocrine secures an injunction or court decisions affirming patent infringement, delaying or preventing Teva’s market entry until patent expiry.

Q5: How does this case compare with similar patent litigations in the pharma industry?
A5: It follows a common pattern of early Paragraph IV challenges, validity disputes, and potential settlement, reflecting industry norms in biosimilar and specialty drug markets.

---

References

1. U.S. Patent and Trademark Office (USPTO) records on cited patents.
2. FDA filings and approvals related to Teva's ANDA submissions.
3. Legal filings from the complaint, motions, and court docket entries in Case No. 1:22-cv-00092.
4. Industry reports on patent litigations in the biosciences segment (e.g., PhRMA studies).
5. Case law: Hatch-Waxman Act provisions and relevant court precedents.

---

[End of Document]